GEO DataSets

(Submitter supplied) We used microarrays to assess gene expression in proliferating ovarian cancer cell lines

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6244

98 Samples

Download data: CEL

(Submitter supplied) Therapeutic targeting of BRAFV600E has shown a significant impact on progression-free and overall survival in advanced melanoma, but only a fraction of patients benefit from these treatments, suggesting that additional signaling pathways involved in melanoma growth/survival need to be identified. In fact MAPK and PI3K/mTOR signaling pathways are constituively activated in most cancers, including melanoma, to sustain the melanoma growth/survival. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10558

24 Samples

Download data: TXT

(Submitter supplied) Poly(ADP-ribose) polymerase inhibitors (PARPi) are now widely used in treating ovarian cancer. However, PARPi resistance emerges gradually. To investigate the change of gene expression during the transition, we have induced a stable resistant cell strain by culturing A2780 in the continued presence of olaparib. We then performed RNA-seq of the resistant strain and its parent line A2780. We found that C/EBPβ was strongly correlated with PARPi resistance. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24676

31 Samples

Download data: TXT

(Submitter supplied) Colorectal cancer (CRC) with high rate of mortality is one of the most commonly diagnosed cancers in worldwide. Advanced colorectal cancer is often accompanied by malignant proliferation of tumor cells. Further researches on colorectal cancer proliferation to find new targets and develop new therapeutic regimen are an important direction for colorectal cancer treatment. In this study, genome-wide RNAi screening was used to discover the essential genes associated with colorectal cancer cell proliferation. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing; Other

Platform:

GPL20795

4 Samples

Download data: BW

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

98 Samples

Download data: CEL

(Submitter supplied) Basal gene expression levels were determined by global gene expression profiling of breast cancer cell lines. Molecular subtype was determined using gene expression and HER2 status assesses by HER2 FISH analysis. Keywords: Basal gene expression (no stimulation or timecourse)

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

51 Samples

Download data: CEL

(Submitter supplied) MCF10A cells were then transfected with MEK1(S217S221), HRAS(G12V), and null control vectors Cells were lysed 24 hours post-transfection with collection of total RNA and protein Keywords: Oncogene inducation of gene expression changes

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

17 Samples

Download data: CEL

(Submitter supplied) We used microarrays to profile 30 human primary breast tumors and determine global gene expression patterns and molecular subtypes Keywords: Basal gene expression in human tumor samples

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

30 Samples

Download data: CEL

(Submitter supplied) Sequencing of olaparib-resistant PEO1 derivatives (C4, C5, C10 and C18) and parental PEO1 (P1 and P2) cells was performed in order to determine mechanisms of acquired resistance in the resistant cell lines. PEO1 parental cell lines were authenticated prior to sequencing. PEO1 parental were confirmed to be BRCA2-mutated (5139C>G). Olaparib PEO1 resistant cells were generated through a step-wise escalation of olaparib (10nM to 8uM olaparib). more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL20301

6 Samples

Download data: TXT

(Submitter supplied) The mTOR (mammalian Target of Rapamycin) pathway is constitutively activated in Diffuse Large B-Cell Lymphoma (DLBCL). mTOR inhibition has been shown to have clinical activity in patients with DLBCL, although overall response rates remain low. We therefore evaluated differences in the transcriptome between DLBCL cell lines with differential sensitivity to the mTOR inhibitor Rapamycin, to (A) identify gene-expression patterns(GEP) capable of identifying sensitivity to Rapamycin, (B) understand the underlying mechanisms of resistance to Rapamycin in DLBCL and (C) identify bioactive molecules likely to synergize with mTOR inhibitors. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4236

Platform:

GPL6244

14 Samples

Download data: CEL, CHP

Analysis of diffuse large B-cell lymphoma (DLBCL) cell lines resistant to rapamycin, the prototypical mTOR (mammalian Target Of Rapamycin) inhibitor. The mTOR pathway is constitutively activated in DLBCL. Results provide insight into mechanisms of resistance to mTOR inhibition in DLBCL.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 14 cell line, 2 other sets

Platform:

GPL6244

Series:

GSE27255

14 Samples

Download data: CEL, CHP

(Submitter supplied) Treatment of established lines and primary ovarian cancer cultures with Src and MEK inhibitors, saracatinib and selumetinib, respectively, showed target kinase inhibition and synergistic induction of apoptosis and cell cycle arrest in vitro and tumor inhibition in xenografts.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10558

12 Samples

Download data: TXT

(Submitter supplied) Background: Resistance to platinum-based chemotherapy remains a major impediment in the treatment of serous epithelial ovarian cancer. The objective of this study was to use gene expression profiling to delineate major deregulated pathways and biomarkers associated with the development of intrinsic chemotherapy resistance upon exposure to standard first-line therapy for ovarian cancer. Methods: The study cohort comprised 28 patients divided into two groups based on their varying sensitivity to first-line chemotherapy using progression free survival (PFS) as a surrogate of response. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4950

Platform:

GPL570

28 Samples

Download data: CEL

Analysis of tumors from high-grade serous ovarian cancer patients resistant or sensitive to platinum-based chemotherapy. Tumor samples collected prior to chemotherapy. Results identify a gene expression profile associated with intrinsic chemotherapy resistance.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 10 disease state, 2 specimen sets

Platform:

GPL570

Series:

GSE51373

28 Samples

Download data: CEL

(Submitter supplied) Triple negative breast cancer (TNBC) is an aggressive subtype that lack targeted clinical therapies. In addition, TNBC is heterogeneous and was recently further sub-classified into seven TNBC subtypes that displayed unique gene expression patterns. To develop therapeutic treatment regimens, we established seven patient-derived xenograft models from TNBC tumors. These xenograft models not only retained the histology and clinical markers of the corresponding patient tumors, but also bearing the same mutations and deletions identified in the patient tumors. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

7 Samples

Download data: CEL

(Submitter supplied) To identify altered signal transduction pathways involved in the progression and metastases of Lkb1 deficient lung tumors, we have performed an unbiased microarray analysis of primary and metastatic mouse lung tumors We used microarrays to detail the global programme of gene expression underlying metastatic progression

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL8321

35 Samples

Download data: CEL

(Submitter supplied) Anticancer drug development is an inefficient process, with potential therapeutics demonstrating a high attrition rate due to lack of efficacy in Phase II/III testing. In an effort to develop improved pre-clinical predictors of efficacy, we and others have turned to testing in genetically engineered murine models (GEMMs) of cancer, which may offer some advantages to in vitro and xenograft systems. Specifically, we assessed the activity of 16 treatment regimens in a Ras-driven, Ink4a/Arf-deficient melanoma GEMM. Like human RAS-mutant melanoma, this GEMM was refractory to standard chemotherapy and single-agent small molecule therapies. Only one regimen exhibited significant anti-tumor activity in this model: combined treatment with AZD6244 (MEK inhibitor) and BEZ235 (dual PI3K/mTOR inhibitor), which produced marked tumor regression and improved survival. Given the surprising activity of the “AZD/BEZ” combination in a melanoma GEMM, we next tested this regimen in a Ras-driven orthotopic-transplant model of “claudin-low” breast cancer, which shares some gene expression features with melanoma. The AZD/BEZ regimen also exhibited significant activity in this related Ras-driven model, leading us to testing in even more diverse GEMMs of basal-like and luminal breast cancer. The AZD/BEZ combination was highly active in each of these distinct breast models, demonstrating equal or greater efficacy compared to any other regimen tested in studies of over 700 tumor-bearing mice. This regimen even exhibited activity in tumors selected for resistance to another effective chemotherapy agent, lapatinib, in HER2+ models. These results demonstrate the utility of credentialed murine models for large-scale efficacy testing of diverse anti-cancer regimens, and predict combinations of PI3K/mTOR and MEK inhibitors will demonstrate anti-tumor activity in a wide-range of human malignancies.

Organism:

Mus musculus

Type:

Expression profiling by array

Platforms:

GPL2881 GPL11383 GPL10732

16 Samples

Download data

(Submitter supplied) A comparison of gene expression in OCT frozen human angiosarcoma compared with OCT frozen normal mesenchymal tissues

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL14550

32 Samples

Download data: TXT

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL571

165 Samples

Download data: CEL, CHP

(Submitter supplied) Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. We used microarrays to find gene expression patterns associated with drug response and also identified genes regulated by the MAP kinase pathway

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL571

24 Samples

Download data: CEL, CHP